SG Americas Securities LLC Increases Stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

SG Americas Securities LLC raised its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 66.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,629 shares of the company’s stock after buying an additional 6,616 shares during the period. SG Americas Securities LLC’s holdings in Enliven Therapeutics were worth $374,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ELVN. The Manufacturers Life Insurance Company purchased a new stake in shares of Enliven Therapeutics in the 2nd quarter worth about $322,000. China Universal Asset Management Co. Ltd. increased its stake in Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock valued at $232,000 after purchasing an additional 3,559 shares in the last quarter. Quest Partners LLC increased its stake in Enliven Therapeutics by 1,226.4% during the 3rd quarter. Quest Partners LLC now owns 21,117 shares of the company’s stock valued at $539,000 after purchasing an additional 19,525 shares in the last quarter. First Turn Management LLC increased its stake in Enliven Therapeutics by 29.5% during the 3rd quarter. First Turn Management LLC now owns 535,092 shares of the company’s stock valued at $13,666,000 after purchasing an additional 121,849 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Enliven Therapeutics by 10.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,277 shares of the company’s stock valued at $6,520,000 after acquiring an additional 24,043 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on ELVN. Robert W. Baird raised their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. BTIG Research started coverage on shares of Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Enliven Therapeutics has a consensus rating of “Buy” and an average target price of $38.25.

Enliven Therapeutics Price Performance

Shares of NASDAQ:ELVN opened at $21.90 on Tuesday. Enliven Therapeutics, Inc. has a 1-year low of $10.90 and a 1-year high of $30.03. The company has a market capitalization of $1.07 billion, a P/E ratio of -11.53 and a beta of 1.04. The firm’s 50 day simple moving average is $23.04 and its two-hundred day simple moving average is $24.27.

Insider Buying and Selling at Enliven Therapeutics

In other news, COO Anish Patel sold 21,700 shares of Enliven Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $24.18, for a total transaction of $524,706.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $24.89, for a total transaction of $130,672.50. The disclosure for this sale can be found here. Insiders have sold 35,450 shares of company stock valued at $845,048 over the last 90 days. 29.20% of the stock is currently owned by corporate insiders.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.